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ABSTRACT: The histone deacetylase inhibitors (HDACis) are a class of
chemically heterogeneous anticancer agents of which suberoylanilide
hydroxamic acid (SAHA) is a prototypical member. SAHA derivatives
may be obtained by three-dimensional manipulation of SAHA aryl cap,
such as the incorporation of a ferrocene unit like that present in Jay Amin
hydroxamic acid (JAHA) and homo-JAHA [Spencer, et al. (2011) ACS
Med. Chem. Lett. 2, 358−362]. These metal-based SAHA analogues have
been tested for their cytotoxic activity toward triple-negative MDA-
MB231 breast cancer cells. The results obtained indicate that of the two
compounds tested, only JAHA was prominently active on breast cancer
cells with an IC50 of 8.45 μM at 72 h of treatment. Biological assays
showed that exposure of MDA-MB231 cells to the HDACi resulted in cell
cycle perturbation with an alteration of S phase entry and a delay at G2/M
transition and in an early reactive oxygen species production followed by mitochondrial membrane potential (MMP) dissipation
and autophagy inhibition. No annexin binding was observed after short- (5 h) and longer (24 and 48 h) term incubation with
JAHA, thereby excluding the promotion of apoptosis by the HDACi. Although caution must be exercised in extrapolation of in
vitro results to the in vivo situation for which research on animals and human trials are needed, nevertheless JAHA treatment
possesses the potential for its development as an agent for prevention and/or therapy of “aggressive” breast carcinoma, thus
prompting us to get more insight into the molecular basis of its antibreast cancer activity.
■ INTRODUCTION
Histones are a group of highly alkaline proteins that bind DNA
and pack it in the characteristic nucleosomal architecture of
chromatin in the eukaryotic cell nuclei. Post-translational
modiﬁcations of histones are known to promote subtle,
precisely regulated alterations of chromatin organization,
thereby modulating the chromatin-mediated processes occur-
ring in the nucleus, such as transcription, replication, and
repair.1 Among the enzymes involved in chromatin remodel-
ling, histone deacetylases (HDACs) catalyze the deacetylation
from lysine residues in the N-terminal ends of nucleosomal
histones, leading to chromatin condensation, thus controlling
the transcriptional activity of numerous genes often associated
with the onset of human diseases, such as inﬂammation, cancer,
and neurodegeneration.2−4 In addition, HDACs also play key
regulatory roles via interactions with nuclear receptors and
transcription factors, such as the retinoblastoma protein and
Max-Mad,5,6 and also control cytoskeleton architecture and
nuclear import via acetylation of tubulin and importin α,7
thereby exerting multifold nonhistone targeted eﬀects in the
intracellular microenvironment. Four classes of HDACs have
been recognized, of which class I comprises four members
(HDAC1, -2, -3, and -8) that are found almost exclusively in
the cell nucleus.8
The histone deacetylase inhibitors (HDACis) are an
emerging class of chemically heterogeneous anticancer agents,
which restore a relaxed, hyperacetylated, chromatin structure
potentially leading to re-expression of silenced genes and/or
silencing of downstream genes, ultimately inducing death,
apoptosis, and cell cycle arrest in cancer cells also via
nonhistone-targeted mechanisms such as perturbations of
p53, cytokine signaling pathways, and angiogenesis.9,10
HDACis are grouped in diﬀerent categories on the basis of
their chemical nature, and the implication of this molecular
diversity is that the precise mechanism through which these
compounds work is still poorly understood. Suberoylanilide
hydroxamic acid (SAHA), a.k.a. Vorinostat, is a prototypical
HDACi targeting class I and II HDAC approved in 2006 by the
Food and Drug Administration for treatment of cutaneous T-
cell lymphoma,11 which has been subjected to several
manipulations of the core structure to probe the eﬀect of
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such modiﬁcations on both HDAC inhibitory activity and
cytotoxic eﬀect on cancer cells. Some of us12 have recently
reported the synthesis of metal-based SAHA analogues
incorporating a ferrocene unit, that is, Jay Amin hydroxamic
acid (JAHA a.k.a. JA47) and homo-JAHA, which, if compared
with parental SAHA, displayed similar broad inhibitory proﬁles
toward class I HDACs, including HDAC8, although homo-
JAHA was less potent toward HDAC6 and more eﬀective
toward HDAC8, whereas none of them was active on class IIa
HDACs. The ability of these compounds to restrain the growth
of the estrogen receptor-positive, low malignant, MCF-7 breast
tumor cells prompted us to extend the investigation to other
neoplastic cell lines, more representative of breast cancer
histotypes with poor outcome, and also to get more insight into
the molecular mechanism of cytotoxic induction.
Triple-negative breast cancers lack expression of estrogen
and progesterone receptors and are human epidermal growth
factor receptor 2 (HER2)/neu negative, thereby being poorly
responsive to hormonal therapies and to HER2-targeting drugs
and usually associated with worse prognosis than other breast
tumor types.13 The MDA-MB231 cell line has been chosen as
the model system for this study, being derived from a pleural
eﬀusion of a triple-negative breast cancer of basal subtype and
displaying several features of an aggressive phenotype, such as
the presence of an inactive mutant form of p53, and the
invasiveness and formation of metastasis in vivo.14,15 Here, we
report that JAHA is more eﬃcient than homo-JAHA as an
anticancer agent toward MDA-MB231 cells, thus being worthy
of further in vivo investigations, and that its cytotoxic activity,
when administered at 72 h half maximal inhibitory concen-
tration (IC50) concentration, sees the involvement of (i) cell
cycle perturbation, possibly related to an inability of cells to
proceed through the G2/M transition, (ii) an early increase of
reactive oxygen species (ROS) production followed by
dissipation of mitochondrial transmembrane potential, and
(iii) the inhibition of the autophagic process.
■ EXPERIMENTAL PROCEDURES
Cell Culture and HDACis. MDA-MB231 breast tumor cells were
maintained in RPMI 1640 medium plus 10% fetal calf serum (FCS),
100 U/mL penicillin, 100 μg/mL streptomycin, and 2.5 mg/L
amphotericin B (Invitrogen, Carlsbad, CA), at 37 °C in a 5% CO2
atmosphere. The cells were detached from ﬂasks with 0.05% trypsin-
EDTA, counted, and plated at the necessary density for treatment after
achieving 60−80% conﬂuency. JAHA and homo-JAHA were
synthesized as reported by Spencer et al.12 and dissolved at 6.5 mM
concentration in dimethyl sulfoxide (DMSO) as stock solutions.
Cell Viability Assay. The assessment of in vitro cytotoxic activity
was determined by an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay (http://www.molmeth.org/protocols/
1VB7RPF). Brieﬂy, MDA-MB231 cells in exponential growth were
plated at a concentration of 5500 cells/well in a 96-well plate and
allowed to adhere overnight. Then, the cells were treated with 0.1, 1,
10, and 100 μM concentration of either drug or with the vehicle
(DMSO) for 24, 48, and 72 h and observed under the phase-contrast
microscope before processing for the viability assay. Diﬀerent amounts
of DMSO, equivalent to those diluting the drugs in the parallel
experiments, were added to cells in the conditions of vehicle-only
treatment. Fifteen microliters of MTT (ﬁnal concentration, 0.75 mg/
mL) was then added, and after incubation, 100 μL of SDS-containing
solubilization buﬀer replaced the MTT-containing culture medium and
dissolved the precipitated violet formazan crystals within metabolically
viable cells. Absorbance of the dissolved dye was measured in an
automated microplate reader at 550 nm. The cell viability ratio was
determined as the ratio between treated cells and untreated controls.
IC50 was calculated with Prism 5.0 software (GraphPad, La Jolla, CA).
Apoptosis Assay. The possible onset of apoptosis was evaluated
using the Annexin V-ﬂuorescein isothiocyanate (FITC) kit (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany) according to manu-
facturer's instructions. Brieﬂy, plated cells were treated with 8.45 μm
JAHA for 5, 24, and 48 h. Then, attached and ﬂoating cells were
collected and resuspended in 100 μL of binding buﬀer 1×/106 cells,
and 10 μL of FITC-annexin V was added. After centrifugation and
resuspension in 500 μL of binding buﬀer 1×, propidium iodide was
added immediately prior to ﬂow cytometric analysis in a FACSCanto
apparatus (BD Biosciences, Franklin Lakes, NJ). Data were
represented as dot plots using Flowing software v.1.6.0., which
discriminated normal cells (bottom left quadrant) from cells in early
apoptosis (bottom right quadrant), cells in late apoptosis or early
necrosis (top right quadrant), or cells undergoing necrosis (top left
quadrant). Vehicle-treated cells were tested as parallel controls.
Cell Cycle Analysis. MDA-MB231 cells were seeded in six-well
plates at a concentration of 88000 cells/well and allowed to adhere
overnight and then treated with 8.45 μm JAHA and harvested after 24
and 48 h of incubation. Cells were resuspended in 0.5% Triton X-100
in phosphate-buﬀered saline containing 0.5 μg/mL RNase A,
incubated a 37 °C for 30 min, and then treated with propidium
iodide at 4 °C for 30 min in the dark. The cell cycle distribution was
analyzed by ﬂow cytometry in a FACSCanto apparatus and Weasel
3.0.1 software. Vehicle-treated cells were tested as parallel controls.
Evaluation of ROS Production. The production of ROS, such as
hydrogen peroxide, peroxynitrite, hydroxyl radicals, nitric oxide, and
peroxy radical, and of superoxide was checked using the Total ROS/
Superoxide Detection Kit (Enzo Life Sciences, Lausen, Switzerland)
according to the manufacturer's instructions. Brieﬂy, attached and
ﬂoating MDA-MB231 cells treated with 8.45 μm JAHA were harvested
after 24 and 48 h of incubation and resuspended in 500 μL of ROS/
Superoxide Detection Mix and incubated for 30 min at 37 °C in the
dark prior to ﬂow cytometry assay for the green and orange
ﬂuorescence in a FACSCanto apparatus. Vehicle-treated cells were
tested as parallel controls. Positive (pyocyanin-treated) and negative
(N-acetyl-L-cysteine-treated) controls were included in the analysis,
and data were represented as dot plots using Flowing software v.1.6.0.,
which discriminate cells with increased total ROS production (top left
quadrant), increased superoxide production (bottom right quadrant),
and increased total ROS and superoxide production (top right
quadrant). To assess the involvement of ROS production in the
cytotoxic eﬀect of JAHA, an MTT assay was performed as already
reported on JAHA-treated cells incubated for 24 h in the presence of
the antioxidant butylated hydroxytoluene (BHT)16 at 5, 10, 25, and 50
μm ﬁnal concentration.
Mitochondrial Membrane Potential (MMP) Assay. Control
and JAHA-treated cell preparations were stained with the ﬂuorescent
dye JC1 (Invitrogen) according to Cannino et al.,17 and MMP was
then checked by ﬂow cytometry, according to Cossarizza and
Salvioli.18 Essentially, control and JAHA-treated MDA-MB231 cells,
both attached and ﬂoating, harvested after 24 and 48 h from treatment,
were stained with JC1 (ﬁnal concentration, 2.5 μg/mL) for 10 min at
37 °C, washed with phosphate-buﬀered saline (PBS), and analyzed for
the green and orange ﬂuorescence in a FACSCanto apparatus. Data
were represented as dot plots using Flowing software v.1.6.0., which
discriminate in the bottom quadrants the amount of cells that undergo
loss of MMP.
Autophagy Assays. Quantiﬁcation of Acidic Vesicular Organ-
elles (AVOs). AVOs, which are a hallmark of autophagy, were
quantiﬁed by ﬂow cytometry as reported by Jiang et al.19 and Chen et
al.20 Essentially, control and JAHA-treated MDA-MB231 cells, both
attached and ﬂoating, were harvested after 24 and 48 h of incubation
and stained with acridine orange (ﬁnal concentration, 100 μg/mL) for
20 min in the dark and then analyzed in a FACSCanto ﬂow cytometer.
Data were represented as dot plots using Flowing software v.1.6.0.,
which discriminate cells with increased AVO accumulation in the top
quadrants. In a parallel set of assays, as a negative control, untreated
cells were incubated with baﬁlomycin A1 (Enzo Life Sciences), a
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macrolide antibiotic that inhibits the vacuolar type H+ ATPase of
AVOs,20 at 200 nM ﬁnal concentration for 30 min before acridine
orange staining.
Western Blot for LC3 and p62/Sequestosome 1 (p62/SQSTM1)
Proteins. Electrophoretic analysis and immunoblots were performed
according to Chiarelli et al.21 Essentially, control and JAHA-treated
cell lysates obtained after 18, 24, and 48 h of culture were submitted to
8% SDS-PAGE and protein transfer onto Hybond-ECL nitrocellulose
membranes (Amersham) using a semidry apparatus (Novablot,
Pharmacia). Immunorevelation was performed with either of the
two primary antibodies, that is, rabbit polyclonal anti-LC3 (L8918,
Sigma, St. Louis, MO; 1:1000) or anti-p62/SQSTM1 (P0068, Sigma;
1:1000), and antiactin antibodies (A5060, Sigma; 1:500) as a loading
control and secondary alkaline phosphatase-conjugated antirabbit IgG
(Fc) antibody (S373B, Promega, Madison, WI), followed by
incubation with 5-bromo-4-chloro-3′-indolyphosphate p-toluidine
salt/nitro-blue tetrazolium chloride (BCIP/NBT) solution (Sigma).
The intensities of the bands of interest, evaluated with ImageJ
software, were normalized for those of actin. Data obtained by protein
blot analysis are presented as means ± standard errors of the mean
(SEMs) of triplicate experiments.
Involvement of Autophagy Inhibition in the Cytotoxic Eﬀect.
JAHA-treated MDA-MB231 cells were incubated for 48 h with 1 nM
rapamycin (Santa Cruz Biotechnology, Santa Cruz, CA), an antibiotic
that increases autophagosome and autolysosome formation,22 and the
reversion of JAHA-triggered cytotoxic eﬀect was monitored by an
MTT assay, as previously reported.23 Control cells were tested in
parallel.
■ RESULTS
In a ﬁrst set of experiments, we checked the eﬀect of dose- and
time-dependent incubation with JAHA and homo-JAHA
(Figure 1A) on MDA-MB 231 cell viability via MTT assay.
As shown in Figure 1B, when cells were exposed for 72 h to
JAHA, this compound caused death in a concentration-
dependent manner with an IC50 = 8.45 μM, and such
concentration was chosen for all of the subsequent biochemical
experiments. On the other hand, after 72 h of treatment, homo-
JAHA at the highest concentration used (i.e., 100 μM) reduced
cell viability only to 63 ± 1.8%. The same concentration of
either JAHA and homo-JAHA determined a decrease of cell
viability to 83.9 ± 5.1 and 83.15 ± 9.7% at 24 h of incubation
and 66.4 ± 6.7 and 61.54 ± 2.09%, respectively. Phase-contrast
microscopical observation of MDA-MB231 cells treated with
8.45 μM JAHA showed visible eﬀects of cell death such as
decreased cell number and the presence of rounded and
ﬂoating cells, with respect to the ﬁrmly spread control cell
preparations (Figure 1C).
Therefore, we performed a set of experiments aimed to get
more detailed data on the molecular mechanism of JAHA-
induced toxicity on MDA-MB231 cells. First, samples of
control and JAHA-treated cells were submitted to annexin V-
FITC/propidium iodide (PI) staining and ﬂow cytometric
measurement to investigate the eﬀect of JAHA on phosphaty-
dilserine externalization, as a hallmark of induction of apoptosis,
after short-term (5 h), and longer term (24 and 48 h)
treatments. As shown in Figure 2, JAHA treatment appeared to
elicit a nonapoptotic cytotoxic eﬀect as indicated by the
increase of the percentage of necrotic cells in both top
quadrants at 48 h of exposure and the almost total absence of
apoptotic annexin+/PI− cells in the bottom right quadrant at all
times of investigation.
Then, we wanted to check which kind of perturbation was
induced by JAHA treatment on the MDA-MB231 cell cycle. To
this purpose, cells treated with JAHA for 24 and 48 h were
stained with PI and subjected to ﬂow cytometric analysis of the
distribution of cell cycle phases. Figure 3 shows that, if
compared to controls, exposure to JAHA was linked with a
higher percentage of cells in the subG0 fraction (66.22 and
47.20% vs 47.86 and 35.11%, respectively, at 24 and 48 h),
consistent with an increase of damaged and fragmented cells
due to compound toxicity more prominent at earlier times, a
pronounced decrease of the S phase fraction (6.68 and 8.28%
vs 19.07 and 20.39%, respectively, at 24 and 48 h) and also of
the 24 h G0/G1 phase fraction (11.55 vs 21.17%). Noteworthy,
ﬂow cytometric analysis also showed an increase of the 48 h G2
phase fraction (15.53 vs 8.23%), indicative of the acquisition of
the inability to proceed through the G2/M transition upon
prolonged incubation.
To detect variations of MMP after exposure to JAHA, we
used the JC1 probe that is selectively uptaken into
mitochondria, undergoing a ﬂuorescence emission shift from
green (∼529 nm) to red (∼590 nm) in the case of intact MMP,
whereas in the case of mitochondrial depolarization, a decrease
in the red/green ﬂuorescence intensity ratio can be observed.17
Figure 1. JAHAs and eﬀect of 72 h of incubation on the viability of
MDA-MB231 cells. (A) Structure of JAHA and homo-JAHA. (B)
Dose−response curves for JAHA and homo-JAHA from triplicate
MTT assays. The results are expressed as means ± SEMs. (C)
Representative phase-contrast micrographs of control and 8.45 μM
JAHA-treated cells showing changes in cell number and morphology
after exposure to JAHA. Bar = 10 μM.
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As shown in Figure 4, ﬂow cytometry analysis puts in evidence
the time-dependent loss of the MMP in JAHA-treated cells, the
percentage of low red-emitting cells (bottom quadrants) being
about 9% after 24 h of exposure and increasing up to about 36%
at 48 h of incubation, versus 2 and 5% of control cells,
respectively. The JAHA ability to aﬀect mitochondrial
metabolism was also assessed through evaluation of ROS
production using a commercial kit, which diﬀerentiates between
total ROS and superoxide. As shown in Figure 5A, exposure to
JAHA determined an early 3-fold increase of total intracellular
ROS within 24 h of incubation; on the other hand, such up-
regulation of total ROS was not recorded at 48 h of treatment.
In addition, although the superoxide-positive fraction of MDA-
MB231 cells treated with JAHA for 48 h was higher than that of
controls (19.69 vs 4.05%), the value was consistently less than
half of that obtained with the pyocyanin-treated sample as
positive control, thereby indicating that the observed up-
regulation of superoxide ion was not signiﬁcant (data not
shown). To check whether the observed ROS up-regulation
could be involved, at least in part, in the onset of JAHA-
triggered cytotoxicity, MDA-MB231 cells were coincubated
with 8.45 μM JAHA and the phenolic antioxidant BHT at
increasing concentrations. The results shown in Figure 5B
demonstrate that the cotreatment was capable of reversing the
decrease in cell number recorded with JAHA-only treatment,
with 25 and 50 μM BHT concentrations, respectively, inducing
a comparable and more pronounced cell growth than that of
the untreated control.
Lastly, we checked whether JAHA determined a modiﬁcation
in the amount of autolysosomes, a hallmark of autophagy,
through staining with acridine orange, a cell-permeable
ﬂuorescent dye that can be sequestered by acidic compartments
after uptake and protonation. Figure 6 shows that JAHA-treated
cells underwent a consistent reduction of AVO accumulation
between 24 and 48 h of exposure and that such a decrease was
comparable to that observed when cells were incubated with
200 nM baﬁlomycin A1, a well-known inhibitor of
autolysosome maturation,24 as a negative control. Autophagy
Figure 2. Flow cytometric analysis of control and JAHA-treated MDA-
MB231 cells stained with annexin V-FITC and PI for detection of
phosphatydilserine externalization after 5, 24, and 48 h of exposure.
The percentage indicated in the four quadrants in each frame refers to
necrotic annexin−/PI+ and annexin+/PI+ cells (both top quadrants),
apoptotic annexin+/PI− cells (bottom right quadrant), and normal
annexin−/PI− cells (bottom left quadrant). Upon treatment, apoptotic
cells never accounted for more than 0.59% of the cell population,
whereas the percentage of necrotic cells showed an increase at long-
term exposure.
Figure 3. DNA proﬁles of control (darker in the background) and
JAHA-treated (lighter superimposed) MDA-MB231 cells after 24 and
48 h of exposure. Cell cycle distribution is reported in the annexed
tables for both cell samples.
Figure 4. Analysis of MMP in control and JAHA-treated MDA-
MB231 cells. Flow cytometric analysis of control and JAHA-treated
MDA-MB231 cells stained with JC1 after 24 and 48 h of exposure.
The percentages indicated in the bottom quadrants in each frame refer
to low red-emitting cells that underwent dissipation of MMP.
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modulation by JAHA treatment was also monitored via
molecular markers through immunoblot analysis. In particular,
we checked (i) the conversion of microtubule-associated
protein light chain 3 (LC3) from its cytosolic form (LC3-I)
to its autophagosome-associated lipidated form (LC3-II), which
diﬀers for its lower molecular mass and can be discriminated
through SDS-PAGE,25 and (ii) the changes in the accumulation
levels of p62/SQSTM1, a receptor for ubiquitinated proteins
that selectively delivers them into the autophagosome and is
known to be a speciﬁc degradation substrate for autophagy.19
After the Western blot, the densitometry of the immunostained
bands was performed with the ImageJ software. The
immunoblot in Figure 7A shows that LC3-II was decreased
in MDA-MB231 cells after 48 h of exposure to JAHA. In
particular, Figure 7B,C reports the densitometric analyses
referred to the LC3-II/LC3-I ratio and also to the LC3-II band
only, as suggested by the advice of Mizishuma and Yoshimori.25
In both cases, although the diﬀerence between control and
exposed cells was not evident at 24 h, apart from a faint
decrease of the band intensity ratio, the increase of the duration
of incubation with JAHA up to 48 h resulted in a reduction of
both the LC3-II/LC3-I ratio and the intensity of LC3-II band
down to about 52 and 71%, respectively, thus conﬁrming the
ﬂow cytometric data. Further evidence of JAHA-induced
autophagy down-regulation was also given by the immuno-
quantitation of p62/SQSTM1. In fact, as shown in Figure 7D,
the p62/SQSTM1 amount in JAHA-treated cells normalized
for that of actin increased by about 50% after 48 h of
incubation, whereas it remained constant at 24 h of culture.
Interestingly, when we evaluated the amount of LC3-I, LC3-II,
and p62/SQSTM1 after shorter term JAHA treatment, that is,
at 18 h from cell plating, we found an increase of the LC3-II/
LC3-I ratio by about 62% and a reduction of p62/SQSTM1
down to about 20% (Figure 8), consistent with an early
autophagy induction, which is then followed by an arrest of the
autophagic ﬂux over 24−48 h of treatment.
To check whether inhibition of the autophagic process could
account, at least in part, for the observed JAHA-triggered lethal
eﬀect on MDA-MB231 cells, cells were coincubated with 8.45
μM JAHA and increasing concentrations of rapamycin
(sirolimus), an antibiotic acting as autophagy promoter via
inhibition of the mammalian target of rapamycin (mTOR), a
serine-threonine kinase that plays a key role in regulating
fundamental cellular activities, such as growth, proliferation,
cytoskeletal architecture, transcription, and translation.26 When
MDA-MB231 cells were coincubated with 8.45 μM JAHA and
1 nm rapamycin, by analogy with BHT treatment, we found
that also this cotreatment was capable of reversing the JAHA-
triggered decrease in cell number (Figure 9), thereby revealing
autophagy inhibition as a further aspect, supplementary to early
ROS production, involved in the cytotoxic eﬀect exerted by the
HDACi under study on MDA-MB231 breast tumor cells.
■ DISCUSSION
Breast tumor is a widely spread neoplastic histotype accounting
for about 20% of all cancers in women; about 15% of breast
cancers are triple-negative, and the lack of receptors for
estrogens, progesterone, and epidermal growth factor renders
neoplastic cells highly aggressive and endowed with a higher
malignant potential than other breast tumor subtypes.27
Because the pharmacological options for treating triple-negative
tumors are limited, there has been great interest in testing novel
drugs or analogues of pre-existing drugs counteracting triple-
negative cell growth, which, on the other hand, necessitate a
comprehensive biological characterization.
SAHA is an archetypal HDACi whose eﬀect on triple-
negative MDA-MB231 breast cancer cells, the model system
used in the present study, has been previously tested. In fact,
data from Huang and Pardee28 and Xu et al.29 demonstrated
that SAHA aﬀected cell cycle progression and induced
polyploidy, the onset of apoptosis, and also the up-regulation
of several proliferation-inhibiting and diﬀerentiation-promoting
Figure 5. Eﬀect of JAHA treatment on ROS production by MDA-
MB231 cells and its involvement in the cytotoxic eﬀect. (A) Flow
cytometric analysis of control and JAHA-treated MDA-MB231 cells
stained with two color ROS detection reagents, after 24 and 48 h of
exposure. The percentage indicated in the four quadrants in each
frame refers to superoxide only overproducing cells (top left
quadrant), total ROS overproducing cells (bottom right quadrant),
and total ROS/superoxide overproducing cells (top right quadrant).
Upon treatment, MDA-MB231 cells undergo a 3-fold up-regulation of
total ROS within 24 h of exposure. The up-regulation of superoxide
ion recorded at 48 h is not signiﬁcant, the value being less than half of
that of pyocyanin-treated sample, used as a positive control (data not
shown). (B) MTT assay of control (A) and JAHA-treated (B−E, black
bars) MDA-MB231 cells assayed in parallel with cells coincubated with
8.45 μM JAHA and BHT at 5, 10, 25, and 50 μM concentrations (B−
E, gray bars). The culture was grown for 24 h, and the assay was made
in triplicate. The results are expressed as means ± SEMs. BHT at 25
and 50 μM concentrations induced a reversal of the cytotoxic eﬀect
exerted by JAHA.
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genes, as assessed through diﬀerential display polymerase chain
reaction (PCR) assays. The role of SAHA in triggering ROS
production and dissipating MMP was reported in other cell
model systems, for example, leukemia and colon carcinoma
cells, although such events always have been associated to the
promotion of apoptosis or autophagy by the HDACi.30−32 In
addition, SAHA was proven to enhance autophagy also in other
neoplastic cytotypes, such as hepatocellular carcinoma,
chondrosarcoma, and glioblastoma cells.33−35
In the present paper, we have tested the cytotoxic eﬀect on
triple-negative MDA-MB231 cells of two ferrocene-containing
SAHA analogues, JAHA and homo-JAHA, already validated for
their in vitro extensive inhibitory activity on class I HDACs,
although to a lesser degree for HDAC8, and class IIb
HDAC6.12 The MTT viability assay demonstrated that if
exposure to MDA-MB231 cells was prolonged to 72 h, JAHA
exhibited an IC50 of 8.45 μM, whereas homo-JAHA, which
diﬀers from JAHA for the presence of an additional methylene
spacer, induced a maximum lowering of cell number down to
about 63% only. Shorter term treatments of cells with JAHA,
Figure 6. Eﬀect of JAHA treatment on AVO accumulation in MDA-MB231 cells. Flow cytometric analysis of control, JAHA-, and baﬁlomycin A1-
treated MDA-MB231 cells stained with acridine orange, after 24 and 48 h of exposure. The percentage indicated refers to AVO-positive cells. JAHA
treatment induced a consistent reduction of AVO accumulation between 24 and 48 h of exposure, comparable to that observed when cells were
incubated with autophagy-inhibitor baﬁlomycin A1.
Figure 7. Eﬀect of JAHA treatment for 24 and 48 h on
autophagosome formation in MDA-MB231 cells. (A) SDS-PAGE
and Western blotting for LC3-I and -II of whole-cell lysates of samples
grown in control conditions or exposed to 8.45 μM JAHA for 24 and
48 h. β-Actin was used as a loading control. (B and C) Histograms
showing the LC3-II/LC3-I ratio (B) and the normalized LC3-II band
intensity (C) of control (black bars) and JAHA-treated (gray bars)
MDA-MB231 cells after 24 and 48 h of culture. The results are
expressed as means ± SEMs of triplicate experiments. (D) SDS-PAGE
and Western blotting for p62/SQSTM1 of whole-cell lysates of
samples grown in control conditions or exposed to 8.45 μM JAHA for
24 and 48 h. β-Actin was used as the loading control.
Figure 8. Eﬀect of JAHA treatment for 18 h on autophagosome
formation in MDA-MB231 cells. Histograms showing the LC3-II/
LC3-I ratio (A) and the normalized p62/SQSTM1 band intensity (B)
of control and JAHA-treated cells.
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that is, 24 and 48 h, determined cell number reduction down to
about only 84 and 66%, respectively (data not shown).
The individuation of a cytotoxic eﬀect exerted by JAHA on
triple-negative cancer cells prompted a more detailed analysis of
its mechanism of action, in particular focusing on cell cycle
perturbation, and the possible onset of apoptosis and/or
autophagy, coupled to ROS overproduction and/or MMP
dissipation. Flow cytometric analysis of cell cycle phases
produced similar data to those obtained on MCF-7 cells,12
which are shared with other HDACi (e.g., SAHA, trichostatin,
apicidin, and psammaplin A), that is, a perturbation of S phase
entry and a delay at G2/M transition,
24,36−39 although in our
model system, we did not observe apoptotic cell death as with
the other HDACi cited, this being a distinctive feature of JAHA.
The most intriguing results on JAHA mechanism of action
regard its ability to induce early ROS production and
subsequent MMP dissipation and autophagy inhibition, and
the reversion of the cytotoxic eﬀect obtained by cotreatment
with either antioxidant or autophagy-promoter compound. It is
well-known that ROS are generated by mitochondria where a
multiplicity of producing sources is existent and where also
ROS detoxifying systems are actively operating; therefore, the
net intracellular amount of ROS derives from the imbalance of
ROS production, removal, and extramitochondrial release.40 It
can be hypothesized that JAHA treatment induces an oxidative
stress due to mitochondrial defense failure, such as structural
impairment and/or loss of matrix solutes (e.g., glutathione)
through the permeability transition pores. On the other hand,
initial ROS production may induce the onset of a “vicious
cycle”,40 that is, a further exacerbation of ROS formation due to
the activation of additional ROS-generating sites within the
mitochondria, which might be directly responsible for the
following MMP collapse as already reported in other cell model
systems41,42 and may be restrained in the presence of the
antioxidant BHT.
Autophagy, that is, the formation of double membrane-
autophagosomes sequestering cytoplasmic material, which is
digested due to subsequent fusion of the vesicles with the
lysosomes, plays a complex role in breast cancer. In fact, some
authors consider autophagy as a tumor suppressor mechanism
leading to cell death, whereas other literature data strongly
support the concept that this process is necessary to provide
energy and basic elements allowing tumor cells to survive under
conditions of metabolic stress, due to oxygen and nutrient
shortage and rapid proliferative rate.22 A number of published
papers suggest that the autophagy rate in MDA-MB231 cells is
constitutively elevated, thereby playing a likely prosurvival role.
For example, it is acknowledged that inhibition of autophagy
sensitizes MDA-MB-231 cells to the lethal eﬀects of chemical
or physical agents (e.g., sulforaphane and capsaicin treatment or
ionizing radiations) and that MDA-MB231 cells are resistant to
rapamycin eﬀects, probably due to their elevated phospholipase
D activity that leads to the formation of phosphatidic acid, a
lipid involved in autophagosome formation.23,43−47 The data
here presented clearly indicate that JAHA can be included in
the list of those molecules that trigger autophagy inhibition and
deprive cells of such a protective mechanism, which can be
restored upon rapamycin coincubation, addressing them to
death. It is known that mitochondria play a central and complex
role in autophagy. Recently, Okamoto48 reported that MMP
plays a role in autophagy regulation and that defective
mitochondria may impair the autophagic ﬂux and vice versa
through a protein kinase A-dependent mechanism. In addition,
Kathiria et al.49 demonstrated that ROS up-regulation following
mitochondrial membrane depolarization led to autophagy
inhibition in human intestinal epithelial cells, and Karantza-
Wadsworth et al.50 proposed that in cases of defective
autophagy, breast tumor cells lose the ability to adapt to
metabolic stress, produce insuﬃcient ATP, and accumulate
damaged mitochondria with excessive ROS. In light of such
evidence, we cannot exclude the occurrence of an interplay
between the early ROS increase, MMP collapse, and autophagy
down-regulation in JAHA-treated MDA-MB231 cells, although
further studies will be required to conﬁrm this hypothesis.
Importantly, Rao et al.51 reported the superior anticancer
activity of cotreating triple-negative breast cancer cells and
xenografts with the pan-HDACi panobinostat and the
autophagy inhibitor chloroquine; therefore, the possible clinical
utilization of the sole JAHA, an HDACi possessing an intrinsic
autophagy-inhibiting activity, appears to be worth investigating.
Noteworthy, the time−course study of JAHA eﬀect on the
control of the autophagic ﬂux revealed a biphasic trend of the
biological progress, whose molecular basis will deserve further
and more detailed investigation.
In conclusion, two diﬀerent SAHA analogues, JAHA and
homo-JAHA, obtained by manipulation of SAHA aryl cap and
assayed for their inhibitory action on puriﬁed HDACs,12 have
been tested for their ability to restrain survival of a triple-
negative breast cancer cell line in vitro. Of the two compounds,
only JAHA exhibited a remarkable activity on MDA-MB231 cell
viability and growth with an IC50 of 8.45 μM at 72 h. This
indicates that the additional methylene spacer present in homo-
JAHA, which in the in tube assay exhibited a similar proﬁle to
that of JAHA for HDACs except HDAC6 and -8, aﬀects its
activity in a cellular environment and underlines the importance
of a detailed biological characterization of promising bio-
inorganic probes for HDACis on speciﬁc cell model systems.
Thus, JAHA, a ferrocene derivative of SAHA, provides a
fascinating tool for studying the interactions of bioorganome-
tallic agents in breast cancer.52,53 The results from biological
assays of JAHA activity highlight the clear involvement of
oxidative damage and autophagy inhibition in cytotoxicity, thus
expanding the list of autophagy-regulating drugs and also giving
Figure 9. Eﬀect of rapamycin cotreatment on JAHA-induced
cytotoxicity on MDA-MB231 cells. MTT assay of control, JAHA-
treated, and JAHA/rapamycin-cotreated MDA-MB231 cells. The
culture was grown for 48 h, and the assay was made in triplicate.
The results are expressed as means ± SEMs. Rapamycin at 1 nM
concentration induced a reversal of the cytotoxic eﬀect exerted by
JAHA.
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an additional example of the role played by autophagy
inhibition in breast cancer cell death.
Although caution must be exercised in extrapolation of in
vitro results to the in vivo situation for which research on
animals and human trials are needed, nevertheless, JAHA
treatment possesses the potential for development as an agent
for prevention and/or therapy of “aggressive” breast carcinoma,
thus prompting us to get more insight into the molecular and
biochemical pathways involved in JAHA antibreast cancer
activity as well as into its possible genotoxic eﬀects and
modulatory functions in angiogenesis and cell invasion, which
will be the object of forthcoming sets of experiments.
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